Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation
Open Access
- 1 December 2012
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (12), 3337-3354
- https://doi.org/10.1111/j.1600-6143.2012.04252.x
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Antibody Mediated Rejection Associated With Complement Factor H–Related Protein 3/1 Deficiency Successfully Treated With EculizumabAmerican Journal of Transplantation, 2012
- Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet countPediatric Nephrology, 2012
- EculizumabDrugs, 2011
- Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2011
- Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutationPediatric Nephrology, 2010
- De novo Thrombotic Microangiopathy in Renal Allograft Biopsies—Role of Antibody-Mediated RejectionAmerican Journal of Transplantation, 2010
- Therapeutic potential of complement modulationNature Reviews Drug Discovery, 2009
- Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndromePediatric Nephrology, 2009
- Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndromePediatric Nephrology, 2009